BACKGROUND: Using chemotherapy as a part of each treatment fraction remains unexplored. This study integrates the concomitant administration of @entity3003 with hyperfractionated irradiation by optimizing chemopotentiation through @entity3003 administration with each irradiation fraction. METHODS: From February 1993 to August 1996, 52 @entity1 with advanced @entity135 were treated on a twice-a-day chemoradiotherapy schedule. Each fraction consisted of 115 cGy preceded by 5 mg/m2 of @entity3003 . Treatment was given 5 days a week up to total doses of 350 mg/m2 of @entity3003 + 8050 cGy in 7 weeks. RESULTS: All (100%) of @entity1 tolerated the treatment (83% as scheduled). Acute and late @entity137 were moderate. Rates of 96% complete response (CR) and 4% partial response (PR) were achieved. At 52 months, local control and cause-specific survival rates are 72% and 59%, respectively. Nodal control rate is 95%. CONCLUSION: These results show potential for improvement upon hyperfractionated radiotherapy alone and compare favorably with those of most reported trials.

Chemotherapy as a part of each treatment fraction in a twice-a-day hyperfractionated schedule: a new chemoradiotherapy approach for advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']
@entity135 :: (MESH:D006258,Disease) :: ['head and neck cancer']
